1,948
Views
0
CrossRef citations to date
0
Altmetric
Editorial

What place will tezepelumab hold in the treatment paradigm in chronic rhinosinusitis?

ORCID Icon, ORCID Icon, , &
Pages 821-825 | Received 28 Feb 2023, Accepted 16 May 2023, Published online: 21 May 2023
 

Abbreviations

ACQ-6=

Asthma Control Questionnaire

AAER=

Annualized Asthma Exacerbation Rate

Arachidonic acid 15-lipoxygenase=

ALOX15, 15-lipoxygenase

ATP=

adenosine triphosphate

CD=

Cluster of differentiation

CRS=

Chronic Rhinosinusitis

CRSwNP=

Chronic Rhinosinusitis with nasal polyps

CRSsNP=

Chronic Rhinosinusitis without nasal polyps

DC=

dendritic cells

FeNO=

Fractional exhaled nitric oxide

MC=

mast cells

IgE=

immunoglobulin

ILC=

innate lymphoid cell

IL=

interleukin

IL-R=

interleukin-receptor

mAb=

monoclonal antibodies

Nitric oxide synthase=

NOS

NP=

nasal polyp

RORα=

RAR-related orphan receptor alpha.

T2=

Type 2

TSLP=

thymic stromal lymphopoietin

TSPLR=

TSLP receptor

Declaration of interest

A Bourdin reports grants, personal fees, non-financial support, and/or other from AstraZeneca and Boehringer Ingelheim; Astra Zeneca, GSK, Novartis, Sanofi Regeneron, Boehringer Ingelheim and Chiesi. C Jeremy reports funding’s by GlaxoSmithKline, Astra Zeneca, Sanofi. L Crampette reports speaker fees, non-financial support and/other from Medtronic, Novartis, Zambon, ALK, AstraZeneca, Sanofi Genzyme. A Engi reports personal fees, non-financial support from Sanofi, Astra Zeneca The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.